Continuous vs. Intermittent Infusion Vancomycin

Status Recruiting

Clinical Trial Summary

Hospitalized adult participants prescribed vancomycin by their treating physician will be randomized to receive vancomycin via continuous or intermittent infusion and measures of kidney function and injury will be collected.

Clinical Trial Description

All study participants regardless of participation status will have been prescribed vancomycin by a treating physician and received a dose per institutional standard of care. Participants will be randomized 1:1 in permuted blocks of 2, 4, or 6 to receive subsequent doses via continuous or intermittent infusion. Participants randomized to intermittent infusion will receive doses per standard of care at infusion rates of 1 gram per hour in every 8,-12, or -24 hour intervals, while participants randomized to continuous infusion will receive a total daily dose infused over a period of 24 hours. Vancomycin concentration will not exceed 5mg/ml and will be infused via central (preferred) or peripheral administration. In order to ensure consistent dosing between study arms, a precision dosing platform will be used by the PI and team to determine total daily doses to best target an AUC of 500 mg x hr/L (range 400-600 mg x hr/L). A single vancomycin concentration will be obtained the following day with Bayesian-guided area-under-the-curve (AUC) monitoring (with dosing adjusted if needed) to ensure vancomycin exposure remains similar between infusion strategies. Both the initiation and discontinuation of vancomycin, as well as any additional therapeutic drug monitoring, will remain at the discretion of the primary clinical team. Glomerular filtration rate (GFR) will be measured on the day of enrollment and day 3 by the administration of 5 ml iohexol (300 mgI/ml) with iohexol plasma concentrations obtained 1 and 4 hours following administration of iohexol. This change in measured GFR between the infusion strategies is the primary outcome of the study. Plasma and urinary markers of kidney function and injury will be obtained the day of enrollment (Day 0) and subsequent days (Days 2-3). If the participant remains on vancomycin 120 hours following enrollment, measured glomerular filtration rate (mGFR) and biomarkers will be assessed again. ;

Study Design

Related Conditions & MeSH terms

Vancomycin

Clinical Trial Details

NCT number	NCT05823116
Study type	Interventional
Source	University of Kentucky
Contact	Alexander H Flannery, PharmD, PhD
Phone	859-562-2766
Email	alex.flannery@uky.edu
Status	Recruiting
Phase	Phase 4
Start date	May 22, 2023
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03221023` - Intrawound Vancomycin Prophylaxis for Neural Stimulator	Phase 2/Phase 3
Recruiting	`NCT03456544` - Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
Not yet recruiting	`NCT05964114` - First Time Right of Vancomycin	N/A
Completed	`NCT02951702` - Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics	Phase 4
Completed	`NCT05535075` - Model-informed Precision Dosing of Vancomycin in Adults	Phase 4
Active, not recruiting	`NCT04911270` - Clinical Decision Support Tool for Vancomycin Dosing in Children	N/A
Recruiting	`NCT02456974` - Antibiotic Dosing in Pediatric Intensive Care
Recruiting	`NCT05257070` - The Clinical Validation of a Dried Blood Spot Method for Vancomycin and Creatinine
Enrolling by invitation	`NCT03585426` - Vancomycin in the Target Site Treatment of Intracranial Infection	Phase 4
Completed	`NCT04756895` - Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population	N/A
Suspended	`NCT02590523` - Intracameral Antibiotic Safety Study	Phase 3
Completed	`NCT03806543` - The Influencing Factors of Vancomycin Trough Level and the Rate Achieving the Target Trough Level
Recruiting	`NCT04758442` - Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology	N/A
Completed	`NCT04042233` - Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol	Phase 4
Active, not recruiting	`NCT04666948` - Precision Dosing of Vancomycin in Critically Ill Children	Phase 4
Recruiting	`NCT02667418` - Optimal Treatment for Recurrent Clostridium Difficile	Phase 4
Recruiting	`NCT06069206` - Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes	N/A
Completed	`NCT03453684` - Pharmacokinetics of Preoperative Vancomycin	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.